407 related articles for article (PubMed ID: 37239077)
21. Prostate cancer, Hu antibodies and paraneoplastic neurological syndromes.
Storstein A; Raspotnig M; Vitaliani R; Giometto B; Graus F; Grisold W; Honnorat J; Vedeler CA
J Neurol; 2016 May; 263(5):1001-1007. PubMed ID: 27007485
[TBL] [Abstract][Full Text] [Related]
22. [Paraneoplastic neurologic syndromes. Diagnostic and pathogenetic significance of autoantibodies].
Kaiser R
Nervenarzt; 1999 Aug; 70(8):688-701. PubMed ID: 10483569
[TBL] [Abstract][Full Text] [Related]
23. Paraneoplastic Neurological Syndromes as Initial Presentation of Tumors: An Eight-Year Single-Center Experience.
Melanis K; Stefanou MI; Kitsos DK; Athanasaki A; Theodorou A; Koropouli E; Keramida A; Dimitriadou EM; Tzanetakos D; Andreadou E; Koutroulou I; Giannopoulos S; Paraskevas GP; Tsivgoulis G; Tzartos JS
J Clin Med; 2024 Jan; 13(3):. PubMed ID: 38337520
[TBL] [Abstract][Full Text] [Related]
24. Paraneoplastic Neurological Syndromes: Transitioning Between the Old and the New.
Gastaldi M; Scaranzin S; Pietro B; Lechiara A; Pesce G; Franciotta D; Lorusso L
Curr Oncol Rep; 2022 Oct; 24(10):1237-1249. PubMed ID: 35476177
[TBL] [Abstract][Full Text] [Related]
25. Central nervous system adverse events of immune checkpoint inhibitors.
Farina A; Villagrán-García M; Vogrig A; Joubert B
Curr Opin Neurol; 2024 Jun; 37(3):345-352. PubMed ID: 38483130
[TBL] [Abstract][Full Text] [Related]
26. Paraneoplastic neurological syndromes associated with renal or bladder cancer: case series and PRISMA-IPD systematic review.
Villagrán-García M; Muñiz-Castrillo S; Ciano-Petersen NL; Vogrig A; Farina A; Villard M; Psimaras D; Alentorn A; Gonçalves D; Fabien N; Rogemond V; Joubert B; Honnorat J
J Neurol; 2023 Jan; 270(1):283-299. PubMed ID: 36050418
[TBL] [Abstract][Full Text] [Related]
27. Antibodies and neuronal autoimmune disorders of the CNS.
Graus F; Saiz A; Dalmau J
J Neurol; 2010 Apr; 257(4):509-17. PubMed ID: 20035430
[TBL] [Abstract][Full Text] [Related]
28. Paraneoplastic neurological syndrome: growing spectrum and relevance.
Ganaraja VH; Rezk M; Dubey D
Neurol Sci; 2022 Jun; 43(6):3583-3594. PubMed ID: 35460452
[TBL] [Abstract][Full Text] [Related]
29. Glutamate receptor antibodies in neurological diseases: anti-AMPA-GluR3 antibodies, anti-NMDA-NR1 antibodies, anti-NMDA-NR2A/B antibodies, anti-mGluR1 antibodies or anti-mGluR5 antibodies are present in subpopulations of patients with either: epilepsy, encephalitis, cerebellar ataxia, systemic lupus erythematosus (SLE) and neuropsychiatric SLE, Sjogren's syndrome, schizophrenia, mania or stroke. These autoimmune anti-glutamate receptor antibodies can bind neurons in few brain regions, activate glutamate receptors, decrease glutamate receptor's expression, impair glutamate-induced signaling and function, activate blood brain barrier endothelial cells, kill neurons, damage the brain, induce behavioral/psychiatric/cognitive abnormalities and ataxia in animal models, and can be removed or silenced in some patients by immunotherapy.
Levite M
J Neural Transm (Vienna); 2014 Aug; 121(8):1029-75. PubMed ID: 25081016
[TBL] [Abstract][Full Text] [Related]
30. Updates in the Management of Paraneoplastic Syndrome.
Verma N; Jaffer MH; Kolli AS; Mokhtari S
Semin Neurol; 2024 Feb; 44(1):36-46. PubMed ID: 38183975
[TBL] [Abstract][Full Text] [Related]
31. Paraneoplastic neurological syndromes associated with non-Hodgkin lymphoma: a case series.
Dinoto A; Cheli M; Catalan M; Olivo S; Scali I; Bertolotti C; Sartori A; Manganotti P
Neurol Sci; 2022 Mar; 43(3):2077-2079. PubMed ID: 35000013
[TBL] [Abstract][Full Text] [Related]
32. [Paraneoplastic neurological syndrome and autoantibodies].
Hayashi Y; Inuzuka T
Brain Nerve; 2013 Apr; 65(4):385-93. PubMed ID: 23568986
[TBL] [Abstract][Full Text] [Related]
33. [Paraneoplastic neurological syndromes in 2008].
Honnorat J
Rev Neurol (Paris); 2009 May; 165 Suppl 3():S59-65. PubMed ID: 19524096
[TBL] [Abstract][Full Text] [Related]
34. [Paraneoplastic Neurologic Syndromes].
Tanaka K
Brain Nerve; 2023 Jun; 75(6):755-762. PubMed ID: 37287359
[TBL] [Abstract][Full Text] [Related]
35. [Pathogenesis of paraneoplastic neurological syndromes].
Tanaka K
Brain Nerve; 2010 Apr; 62(4):309-18. PubMed ID: 20420170
[TBL] [Abstract][Full Text] [Related]
36. Opsoclonus-Myoclonus With Anti-YO Antibodies Revealing Breast Cancer: A Case Report.
Samah Y; Sahar B; Mebrouk Y
Cureus; 2024 May; 16(5):e60452. PubMed ID: 38883074
[TBL] [Abstract][Full Text] [Related]
37. Epidemiology of paraneoplastic neurological syndromes: a population-based study.
Vogrig A; Gigli GL; Segatti S; Corazza E; Marini A; Bernardini A; Valent F; Fabris M; Curcio F; Brigo F; Iacono D; Passadore P; Rana M; Honnorat J; Valente M
J Neurol; 2020 Jan; 267(1):26-35. PubMed ID: 31552550
[TBL] [Abstract][Full Text] [Related]
38. Updated Diagnostic Criteria for Paraneoplastic Neurologic Syndromes.
Graus F; Vogrig A; Muñiz-Castrillo S; Antoine JG; Desestret V; Dubey D; Giometto B; Irani SR; Joubert B; Leypoldt F; McKeon A; Prüss H; Psimaras D; Thomas L; Titulaer MJ; Vedeler CA; Verschuuren JJ; Dalmau J; Honnorat J
Neurol Neuroimmunol Neuroinflamm; 2021 Jul; 8(4):. PubMed ID: 34006622
[TBL] [Abstract][Full Text] [Related]
39. Paraneoplastic Neuropathies: What's New Since the 2004 Recommended Diagnostic Criteria.
Zoccarato M; Grisold W; Grisold A; Poretto V; Boso F; Giometto B
Front Neurol; 2021; 12():706169. PubMed ID: 34659082
[TBL] [Abstract][Full Text] [Related]
40. Autoimmune central nervous system paraneoplastic disorders: mechanisms, diagnosis, and therapeutic options.
Dropcho EJ
Ann Neurol; 1995 May; 37 Suppl 1():S102-13. PubMed ID: 8968221
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
